Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Core观点 - Corcept Therapeutics Incorporated is facing a securities fraud class action lawsuit due to undisclosed concerns from the FDA regarding its drug relacorilant's effectiveness in treating hypertension in patients with hypercortisolism [1] 分组1 - The lawsuit alleges that between October 31, 2024, and December 30, 2025, Corcept failed to disclose critical information from the FDA [1] - The FDA expressed concerns about the adequacy of the program assessing relacorilant's effectiveness, including issues with the design of the pivotal "GRACE" trial study [1] - The FDA indicated that significant issues were expected during the review if Corcept submitted the New Drug Application (NDA) [1] 分组2 - As a result of these undisclosed issues, the positive statements made by Corcept regarding its business, operations, and prospects were deemed materially misleading [1] - Investors who suffered losses related to Corcept are encouraged to participate in the ongoing lawsuit, with a lead plaintiff deadline set for April 21, 2026 [1]